| Literature DB >> 31250572 |
Jin Kyu Kang1,2, Songwon Seo3, Young Woo Jin4.
Abstract
Radon is a naturally occurring radioactive material that is formed as the decay product of uranium and thorium, and is estimated to contribute to approximately half of the average annual natural background radiation. When inhaled, it damages the lungs during radioactive decay and affects the human body. Through many epidemiological studies regarding occupational exposure among miners and residential exposure among the general population, radon has been scientifically proven to cause lung cancer, and radon exposure is the second most common cause of lung cancer after cigarette smoking. However, it is unclear whether radon exposure causes diseases other than lung cancer. Media reports have often dealt with radon exposure in relation to health problems, although public attention has been limited to a one-off period. However, recently in Korea, social interest and concern about radon exposure and its health effects have increased greatly due to mass media reports of high concentrations of radon being released from various close-to-life products, such as mattresses and beauty masks. Accordingly, this review article is intended to provide comprehensive scientific information regarding the health effects of radon exposure. © Copyright: Yonsei University College of Medicine 2019.Entities:
Keywords: Radon; inhalation exposure; lung neoplasm
Mesh:
Substances:
Year: 2019 PMID: 31250572 PMCID: PMC6597470 DOI: 10.3349/ymj.2019.60.7.597
Source DB: PubMed Journal: Yonsei Med J ISSN: 0513-5796 Impact factor: 2.759
Radon Exposure and Lung Cancer Risk among Underground Miners with Occupational Exposure
| Country | Author | Year of publication | Sample size | Person-years of exposure | No. of lung cancers cases | ERR/100 WLM (95% CI) |
|---|---|---|---|---|---|---|
| Combined study | BEIR IV | 1988 | 22562 | 433019 | 459 | 1.3 (0.8, 2.3) |
| ICRP 65 | 1993 | 31486 | 635022 | 1047 | 1.34 (0.82, 2.13) | |
| BEIR VI | 1999 | 60606 | 888906 | 2674 | 0.55 (0.27, 1.13) | |
| UNSCEAR | 2009 | 128634 | 3246467 | 5715 | 0.59 (0.35, 1.00) | |
| Lane, et al. | 2019 | Low cumulative radon exposure <100 WLM | 394236 | 408 | 2.2 (1.3, 3.4) | |
| Canada | Keil, et al. | 2015 | 4124 | 130000 | 617 | 1.17 (1.15, 1.17) |
| Navaranjan, et al. | 2016 | 28546 | 805650 | 1230 | 0.64 (0.43, 0.85) | |
| Czech Republic | Tomasek | 2012 | 9978 | 308910 | 1141 | 0.97 (0.74, 1.27) |
| France | Laborde-Castérot, et al. | 2014 | 5086 | 153063 | 159 | 0.53 (0.19, 1.07) |
| Rage, et al. | 2018 | 5400 | 186994 | 211 | 0.73 (0.32, 1.33) | |
| Germany | Walsh, et al. | 2010 | 58987 | 1997041 | 3016 | 0.20 (0.17, 0.22) |
| Kreuzer, et al. | 2015 | 5504 | 158383 | 159 | 3.39 (-0.01, 6.78) | |
| Sweden | Jonsson, et al. | 2010 | 5486 | 170204 | 122 | 2.20 (0.23, 3.77) |
ERR, excess relative risk; WLM, working level month; CI, confidence interval; BEIR, Biological Effects of Ionizing Radiations; ICRP, International Commission on Radiological Protection; UNSCEAR, United Nations Scientific Committee on the Effects of Atomic Radiation.
Case-Control Studies Regarding the Relationship between Residential Radon Exposure and Lung Cancer Risk
| Country | Author | Year of publication | Study design | Sample size (Case/Control) | Grouping (Bq/m3) | Risk estimate (95% CI) |
|---|---|---|---|---|---|---|
| China | Wang, et al. | 2002 | Case-control | 768/1659 | 100 | OR |
| 1.19 (1.05, 1.47) | ||||||
| Czech Republic | Tomasek | 2013 | 100 | ERR | ||
| Case-control | 370/1399 | 0.14 (0.03, 0.39)* | ||||
| Never smoker | 58/670 | 0.73 (0.02, 1.90)* | ||||
| Ever smoker | 312/729 | 0.14 (0.02, 0.30)* | ||||
| France | Baysson, et al. | 2004 | Case-control | 486/984 | 100 | ERR |
| 0.04 (-0.01, 0.11) | ||||||
| Spain | Barros-Dios, et al. | 2012 | Case-control | 349/513 | OR | |
| <50 | 1.00 | |||||
| 50–00 | 1.87 (1.21, 2.88) | |||||
| 101–147 | 2.25 (1.32, 3.84) | |||||
| >147 | 2.21 (1.33, 3.69) | |||||
| Torres-Durán, et al. | 2014 | Case-control | 192/329 | OR | ||
| Never smoker | ≤100 | 1.00 | ||||
| 101–147 | 0.80 (0.43, 1.50) | |||||
| 148–199 | 1.16 (0.64, 2.11) | |||||
| ≥200 | 2.42 (1.45, 4.06) | |||||
| UK | Darby, et al. | 1998 | Case-control | 982/3185 | 100 | ERR |
| 0.12 (-0.05, 0.33) | ||||||
| USA | Sandler, et al. | 2006 | Case-control | 1474/1811 | 100 | ERR |
| 0.002 (-0.21, 0.21) | ||||||
| Wilcox, et al. | 2008 | Case-control | 651/740 | 100 | OR | |
| 1.05 (0.86, 1.56) |
CI, confidence interval; OR, odds ratio; ERR, excess relative risk; UK, United Kingdom; USA, United States of America.
*90% confidence interval.
Pooled Studies Regarding Residential Radon Exposure and Lung Cancer Risk
| Author | Year of publication | No. of studies | Sample size (Case/Control) | Grouping (Bq/m3) | Risk estimate (95% CI) |
|---|---|---|---|---|---|
| Lubin, et al. | 1997 | 8 | 4263/6612 | 150 | ERR 0.14 (0.0, 0.3) |
| Pavia, et al. | 2003 | 17 | NR | Adjusted OR | |
| 50 | 1.07 (1.04–1.11) | ||||
| 100 | 1.15 (1.07–1.24) | ||||
| 150 | 1.24 (1.11–1.38) | ||||
| 200 | 1.33 (1.15–1.354) | ||||
| 250 | 1.43 (1.19–1.72) | ||||
| Lubin, et al. | 2004 | 2 | 1050/1996 | 100 | OR 1.33 (1.01, 1.36) |
| Krewski, et al. | 2005 | 7 | 3662/4966 | 100 | OR 1.11 (1.00, 1.28) |
| Darby, et al. | 2006 | 13 | 7148/14208 | 100 | ERR 0.08 (0.03, 0.16) |
| Zhang, et al. | 2012 | 22 | 13380/21102 | 100 | ERR 0.07 (0.04, 0.10) |
| Lorenzo-González, et al. | 2019 | Never smokers in Spain | 523/892 | OR | |
| ≤100 | 1.00 | ||||
| 101–147 | 1.14 (0.80, 1.64) | ||||
| 148–199 | 1.25 (0.85, 1.85) | ||||
| ≥200 | 1.73 (1.27, 2.35) |
CI, confidence interval; ERR, excess relative risk; NR, not reported; OR, odds ratio.
Epidemiologic Studies Regarding the Relationship between Radon Exposure and Hematologic Cancer Risk
| Country | Author | Year of publication | Type of leukemia | Sample size (Case/Control) | Grouping (Bq/m3) | Risk estimate (95% CI) |
|---|---|---|---|---|---|---|
| Sweden | Stjernfeldt, et al. | 1987 | ALL, AML | 7/7 | - | Case 156 Bq/m3 |
| Control 333 Bq/m3 | ||||||
| USA | Lubin, et al. | 1998 | ALL | 281/281 (matched) | >148 vs. <37 | ERR: 0.02 (-0.5, 1.0) |
| 505/443 (unmatched) | ERR: 0.44 (-0.1, 1.3) | |||||
| Germany | Kaletsch, et al. | 1999 | Acute leukemias | 82/209 | > 70 vs. <70 | OR 1.30 (0.32, 5.33) |
| Canada and USA | Steinbuch, et al. | 1999 | AML | 173/254 | >100 vs. <37 | OR 1.1 (0.6, 2.0) |
| UK | Law, et al. | 2000 | Acute leukemias | 578/983 | >200 vs. <25 | OR 0.90 (0.31, 2.62) |
| UK | UK Childhood Cancer Study Investigators | 2002 | ALL | 805/1306 | >30 vs. <8 | OR: 0.77 (0.61, 0.99) |
| Other leukemias | 146/232 | OR: 0.71 (0.43, 1.19 | ||||
| Denmark | Raaschou-Nielsen | 2008 | ALL | 860/1720 | >178 vs. <52 (for 5 yr-old child) | ERR: 0.63 (0.05, 1.53) |
| ANLL | 150/300 | ERR: -0.40 (-0.75, 0.41) | ||||
| Chronic leukemias | 143/286 | ERR: 0.36 (-0.52, 2.83) | ||||
| Switzerland | Hauri, et al. | 2013 | All leukemias | 283 (cohort) | ≥139.9 vs. <77.7 | HR: 0.95 (0.63, 1.43) |
| ALL | 225 (cohort) | HR: 0.90 (0.56, 1.43) | ||||
| Norway | Del Risco Kollerud, et al. | 2014 | All leukemias | 431 (cohort) | <50 | HR 1.00 |
| 50–100 | 1.05 (0.82, 1.33) | |||||
| >100 | 1.06 (0.82, 1.39) | |||||
| Per 100 | 0.99 (0.86, 1.13) | |||||
| USA | Teras, et al. | 2016 | All hematologic cancers | 1308 (women's cohort) | <74 | HR 1.00 |
| 74–<100 | 0.97 (0.78, 1.21) | |||||
| 100–124 | 1.37 (1.07, 1.75) | |||||
| 125–148 | 1.39 (0.96, 2.02) | |||||
| >148 | 1.63 (1.23, 2.18) | |||||
| Per 100 | 1.38 (1.15, 1.65) |
CI, confidence interval; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; USA, United States of America; ERR, excess relative risk; OR, odds ratio; UK, United Kingdom; ANLL, acute nonlymphocytic leukemia; HR, hazard ratio.